Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(34 sites)
United States
Mayo Clinic Hospital, Phoenix, Arizona Stanford University, Palo Alto, California UCLA Healthcare Hematology-Oncology, Santa Monica, California Sarah Cannon Research Institue At Healthone, Denver, Colorado Florida Cancer Specialists, Sarasota, Florida Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore, Maryland Dana Farber Cancer Institute, Boston, Massachusetts Hackensack University Medical Center, Hackensack, New Jersey Weill Cornell Medicine, New York, New York Memorial Sloan Kettering Cancer Center, New York, New York Jefferson University Hospitals, Philadelphia, Pennsylvania Scri Oncology Partners, Nashville, Tennessee Md Anderson Cancer Center, Houston, Texas Australia
Chris Obrien Lifehouse, Camperdown, New South Wales St Vincent'S Hospital Sydney, Darlinghurst, New South Wales The Alfred Hospital, Melbourne, Victoria Peter Maccallum Cancer Centre, North Melbourne, Victoria Linear Clinical Research, Nedlands, Western Australia Belgium
Cliniques Universitaires Ucl Saint-Luc, Brussels Universitair Ziekenhuis Antwerpen (Uza), Edegem Universitair Ziekenhuis (Uz) Leuven, Leuven Canada
The Ottawa Hospital Cancer Center, Ottawa, Ontario Princess Margaret Cancer Center, Toronto, Ontario France
Universitaire Du Cancer de Toulouse Institut Claudius Regaud Iuct-Oncopole, Toulouse Institut Gustave Roussy, Villejuif Italy
Fondazione Irccs Istituto Nazionale Dei Tumori, Milan Irccs Istituto Clinico Humanitas, Rozzano Centro Ricerche Cliniche Di Verona, Verona Japan
National Cancer Center Hospital East, Chiba The Cancer Institute Hospital of Jfcr, Tokyo Spain
Hospital General Universitario Vall D Hebron, Barcelona Fundacion Jimenez Diaz, Madrid Hospital Universitario Quironsalud Madrid, Madrid